Grifols, S.A. is set to announce its latest quarterly earnings on Wednesday, April 29th, with a consensus estimate EPS of 0.1613.
Today, Grifols, S.A. is trading at $8.09, showing a price change of -4 cents (-0.492%) from the previous close at $8.13. The trading volume stands at $343,623, representing 47% of the average volume.
The company's latest quarterly earnings were reported on Tuesday, February 24th, with a consensus estimate EPS of 0.29. Stay tuned for the upcoming earnings release on April 29th.
Grifols, S.A. offers an attractive forward dividend yield of 8.69%, with a dividend per share of 17.579 cents both on a quarterly and trailing twelve months basis.
Key financial metrics for Grifols, S.A. include a gross profit margin of 34.68%, return on equity of 1.86%, and a price-to-earnings ratio of 18.75. The company demonstrates a healthy cash position with cash per share at $1.2 and a price-to-book ratio of 1.4.
Stay tuned for the earnings announcement on April 29th to gauge the impact on the asset's performance.
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.